Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tandem Diabetes Care (TNDM – Research Report), Lemai...

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Lemaitre Vascular (LMAT) and Shattuck Labs (STTK)

Shattuck Labs, Inc. ( ($STTK) ) has released its Q3 earnings. Here is a breakdown of the information Shattuck Labs, Inc. presented to its investors...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STTK	$2.03	+5.18%	93.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STTK	$2.03	+5.2%	93.71K
3
4
5
6

STTK

STTK

Dividend Overview

Get Shattuck Labs Inc. Data in Excel

Get Shattuck Labs Inc. Data in Excel